J. Knafels

发表

Sequence analysis of the cis-regulatory regions of the bithorax complex of Drosophila.

E. Lewis, S. Celniker, D. Mathog, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Azetidine and Piperidine Carbamates as Efficient, Covalent Inhibitors of Monoacylglycerol Lipase.

Timothy L. Foley, K. Fennell, J. Pandit, 2017, Journal of medicinal chemistry.

Crystal structure of LpxC from Pseudomonas aeruginosa complexed with the potent BB‐78485 inhibitor

I. Mochalkin, J. Knafels, Sandra Lightle, 2008, Protein science : a publication of the Protein Society.

Insights into Mechanism of Glucokinase Activation

M. Ammirati, J. Pfefferkorn, S. Greasley, 2012, The Journal of Biological Chemistry.

Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences

J. D. Clark, M. Hegen, M. Dowty, 2020, Scientific Reports.

Ligand-protein interactions of selective casein kinase 1δ inhibitors.

K. Walton, M. Hayward, Travis T Wager, 2013, Journal of medicinal chemistry.

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

M. Ammirati, J. Treadway, S. Liras, 2011 .

Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK).

J. Pandit, J. Culp, K. Parris, 2017, Journal of medicinal chemistry.

Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.

S. Wright, J. D. Clark, M. Hegen, 2020, Journal of medicinal chemistry.

Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes

D. Bechtold, A. Loudon, E. Maywood, 2010, Proceedings of the National Academy of Sciences.

Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.

J. Warmus, J. Bronstein, S. Murphy, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a Series of Pyrimidine Carboxamides as Inhibitors of Vanin-1.

Stephen J. Wright, Hong Wang, K. Parris, 2021, Journal of medicinal chemistry.

Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria.

V. Shanmugasundaram, M. Huband, Ye Che, 2014, Journal of medicinal chemistry.

Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.

V. Shanmugasundaram, K. Leach, M. Huband, 2012, Journal of medicinal chemistry.

Potent inhibitors of LpxC for the treatment of Gram-negative infections.

V. Shanmugasundaram, J. Warmus, K. Leach, 2012, Journal of medicinal chemistry.

Complete sequence of the bithorax complex of Drosophila.

E. Lewis, S. Celniker, M. Palazzolo, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Macrocyclic Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonists.

F. Vajdos, M. Schnute, M. Vazquez, 2023, ACS medicinal chemistry letters.

Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.

David C. Wood, K. Fennell, R. Kurumbail, 2018, Journal of medicinal chemistry.

Crystal structure of the bacterial protein export chaperone SecB

Zhaohui Xu, K. Yoshino, J. Knafels, 2000, Nature Structural Biology.

Crystal Structure of the Herpes Simplex Virus 1 DNA Polymerase*

Eric T Baldwin, Xiayang Qiu, E. Baldwin, 2006, Journal of Biological Chemistry.

Sequence analysis of the cis-regulatory regions of the bithorax complex of Drosophila

Susan E. Celniker, David R. Mathog, E. B. Lewis, 1995 .

Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.

J. Bauman, J. Telliez, J. Chrencik, 2018, Journal of medicinal chemistry.

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).

Li Xing, Eddine Saiah, David Lin, 2018, Journal of medicinal chemistry.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring.

Mostofa A Hena, B. Finzel, R. Gilbertsen, 2012, Bioorganic & medicinal chemistry letters.

Structural studies identify angiotensin II receptor blocker-like compounds as branched-chain ketoacid dehydrogenase kinase inhibitors

B. L. Kormos, P. Sahasrabudhe, R. Sommese, 2023, The Journal of biological chemistry.

Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.

K. Gajiwala, M. Hickey, J. Pfefferkorn, 2013, Bioorganic & medicinal chemistry letters.

A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists

D. Buhl, J. Pandit, P. Chanda, 2016, Molecular Pharmacology.

An Intracellular Allosteric Modulator Binding Pocket in SK2 Ion Channels Is Shared by Multiple Chemotypes.

Jerry R. Hobbs, J. Pandit, R. Horst, 2018, Structure.

Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose.

J. Pandit, K. Parris, David A. Price, 2020, Journal of medicinal chemistry.

Small molecule branched-chain ketoacid dehydrogenase kinase (BDK) inhibitors with opposing effects on BDK protein levels

Jake E. Delmore, A. Kalgutkar, B. L. Kormos, 2023, Nature communications.

Casein kinase 1δ/ε inhibitor PF-5006739 attenuates opioid drug-seeking behavior.

K. Walton, Travis T Wager, J. Ohren, 2014, ACS Chemical Neuroscience.